Skip to main content
. 2016 Nov 10;46(2):203–208. doi: 10.1097/MPA.0000000000000742

FIGURE 1.

FIGURE 1

Percentage change in tumor burden from baseline to nadir. The percent change in the sum of the longest diameters of the primary pancreatic (A) or metastatic (B) target lesions was calculated from baseline to nadir in the evaluable population for the gemcitabine monotherapy and nab-paclitaxel plus gemcitabine groups.